Who is sponsoring NCT03559621?

NCT03559621 is sponsored by Universitaire Ziekenhuizen KU Leuven.

What drugs are being tested in NCT03559621?

Interventions in NCT03559621: mobile-based lifestyle intervention.

What condition does NCT03559621 study?

NCT03559621 studies Gestational Diabetes, Type 2 Diabetes Mellitus, Glucose Intolerance, Healthy Lifestyle.

Is NCT03559621 still recruiting?

NCT03559621 is currently completed. Last updated 15 September 2023.

Last reviewed 2023-09-15 · How we verify

NCT03559621: MELINDA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mobile-based Lifestyle Intervention in Women With Glucose Intolerance After Gestational Diabetes

Completed NA Last updated 15 September 2023

What this trial tests

NA trial testing mobile-based lifestyle intervention in Gestational Diabetes in 240 participants. Completed in 6 June 2023.

Timeline

14 April 2019

Primary endpoint
5 May 2023

6 June 2023

Quick facts

Lead sponsor	Universitaire Ziekenhuizen KU Leuven
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	240
Start date	14 April 2019
Primary completion	5 May 2023
Estimated completion	6 June 2023
Sites	7 locations across Belgium

Drugs / interventions tested

mobile-based lifestyle intervention

Conditions studied

Gestational Diabetes — all drugs for Gestational Diabetes →
Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Glucose Intolerance — all drugs for Glucose Intolerance →
Healthy Lifestyle — all drugs for Healthy Lifestyle →

Sponsor

Universitaire Ziekenhuizen KU Leuven — full company profile →

Who can join

18 and older, female only, with Gestational Diabetes or Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Although lifestyle modification programs have been shown to be effective in preventing diabetes in older populations, interventions in women with recent gestational diabetes (GDM) clearly need to be adapted to address their unique barriers to behavior change in order to optimize adherence. The low participating rates in many studies using individual or group sessions, reflect how difficult it is to engage women in the first years postpartum. Since women with glucose intolerance (prediabetes) have the highest risk to develop type 2 diabetes (T2DM), we designed the MELINDA pilot study, a randomized controlled trial with 1 year of follow-up to evaluate the efficacy and feasibility of a telephone -and mobile (app) based lifestyle coaching intervention in women with glucose intolerance after a recent history of GDM to promote a healthy lifestyle.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Mobile-Based Lifestyle Intervention in Women with Glucose Intolerance after Gestational Diabetes Mellitus (MELINDA), A Multicenter Randomized Controlled Trial: Methodology and Design.
Minschart C, Maes T, De Block C, Van Pottelbergh I, et al · · 2020 · cited 13× · PMID 32823771 · DOI 10.3390/jcm9082635
Effectiveness of a blended mobile-based lifestyle intervention in women with glucose intolerance after a recent history of gestational diabetes (MELINDA): a 1-year, prospective, multicentre, randomised controlled trial.
Minschart C, Myngheer N, Maes T, De Block C, et al · · 2024 · cited 12× · PMID 38495521 · DOI 10.1016/j.eclinm.2024.102523
Lifestyle intervention to prevent type 2 diabetes after a pregnancy complicated by gestational diabetes mellitus: a systematic review and meta-analysis update.
Bracco PA, Reichelt AJ, Alves LF, Vidor PR, et al · · 2025 · cited 9× · PMID 39980013 · DOI 10.1186/s13098-025-01606-x
Impact of breastfeeding on risk of glucose intolerance in early postpartum after gestational diabetes.
Vanlaer Y, Minschart C, Vrolijk H, Van Crombrugge P, et al · · 2024 · cited 2× · PMID 38933819 · DOI 10.3389/fendo.2024.1374682
The One-Hour Oral Glucose Tolerance Test to Predict Glucose Intolerance Postpartum in Women With Prior Gestational Diabetes.
Bochanen N, Vanlaer Y, Minschart C, Willems M, et al · · 2026 · PMID 41804216 · DOI 10.1111/dom.70634
Diabetes Risk Perception in Women with a Recent History of Gestational Diabetes Mellitus: A Secondary Analysis from a Belgian Randomized Controlled Trial (MELINDA Study).
Vanlaer Y, Minschart C, Snauwaert I, Myngheer N, et al · · 2025 · PMID 40725690 · DOI 10.3390/jcm14144998
Mental Health and Metabolic Outcomes in Early Postpartum in Women with Prediabetes After Gestational Diabetes: A Secondary Analysis of the MELINDA Trial.
Vanlaer Y, Minschart C, Van den Keybus K, Myngheer N, et al · · 2025 · PMID 40429596 · DOI 10.3390/jcm14103592

Verify or expand the search:

Other recruiting trials for Gestational Diabetes

Currently open trials in the same condition.

NCT07171684 — Single vs Multi-Dose Insulin for Glycemic Control (SUGAR) · NA · recruiting
NCT07314944 — Maternal Sleep and Lifestyle, Metabolic Health, and Perinatal Outcomes in Gestational Diabetes · recruiting
NCT06571487 — Growth Hormone Resistance of Beta-cells · recruiting
NCT07336914 — Effect of Conventional vs Intensive Management on Gestational Diabetes and Maternal Fetal Outcomes · NA · recruiting
NCT07174245 — Pregnancy and Postpartum CGM in GDM · recruiting

Other Universitaire Ziekenhuizen KU Leuven trials

Trials by the same sponsor.

NCT06831955 — LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer · Phase 2 · recruiting
NCT07356505 — Efficacy and Safety of Micra AV2 Transcatheter Pacing System · NA · recruiting
NCT07286968 — Gastro-Intestinal Digestion and Physiology After Bariatric Surgery · recruiting
NCT06962137 — Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer · Phase 2 · recruiting
NCT07270536 — Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03559621 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitaire Ziekenhuizen KU Leuven
Last refreshed: 15 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03559621.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing